市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 看涨 | 混合的 |
| Biotechnology (全球的) | 看涨 | 混合的 | |
| 股票 | Tyra Biosciences, Inc. | 看涨 | 看涨 |
AIStockmoo 评分
| 分析师共识 | 4.0 |
| 内部交易活动 | NA |
| 价格波动 | -3.0 |
| 技术平均移动指标 | -1.0 |
| 技术振荡指标 | 2.0 |
| 平均 | 0.50 |
|
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology. The company’s in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are TYRA-300, TYRA-200, and TYRA-430: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Value |
| 内部持股比例 | 3.69% |
| 机构持股比例 | 108.46% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Nextech Invest, Ltd. | 31 Dec 2025 | 4,055,861 |
| Alta Partners Management Company, L.P. | 31 Dec 2025 | 3,823,425 |
| Commodore Capital Lp | 31 Dec 2025 | 3,375,000 |
| Canaan Partners Xi Llc | 31 Dec 2025 | 3,374,329 |
| Tcg Crossover Management, Llc | 31 Dec 2025 | 2,898,103 |
| Bvf Inc/Il | 31 Dec 2025 | 2,127,665 |
| Farallon Capital Management Llc | 31 Dec 2025 | 2,066,818 |
| Kynam Capital Management, Lp | 31 Dec 2025 | 1,564,492 |
| 5Am Venture Management, Llc | 31 Dec 2025 | 1,029,298 |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 59.00 (Barclays, 77.12%) | 购买 |
| 中 | 47.50 (42.60%) | |
| 低 | 42.00 (Piper Sandler, 26.09%) | 购买 |
| 平均值 | 48.67 (46.11%) | |
| 总计 | 6 购买 | |
| 平均价格@调整类型 | 30.17 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| HC Wainwright & Co. | 17 Feb 2026 | 45.00 (35.09%) | 购买 | 29.12 |
| Wedbush | 13 Feb 2026 | 53.00 (59.11%) | 购买 | 27.99 |
| 16 Dec 2025 | 37.00 (11.08%) | 购买 | 22.97 | |
| Jefferies | 03 Feb 2026 | 43.00 (29.09%) | 购买 | 31.24 |
| Oppenheimer | 03 Feb 2026 | 50.00 (50.11%) | 购买 | 31.24 |
| Barclays | 28 Jan 2026 | 59.00 (77.12%) | 购买 | 31.08 |
| Piper Sandler | 23 Jan 2026 | 42.00 (26.09%) | 购买 | 30.37 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合